ClinicalTrials.gg

Program

KRAS G12D Inhibitor INCB161734

Its studies are mostly in Hepatic Insufficiency · Pancreatic Neoplasms · Renal Insufficiency · Colorectal Neoplasms, led by Incyte.

Furthest: phase 3, since Apr 3, 20265 company-led studies, 4 open or runningNext primary completion: Jan 1, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Incyte54 open or runningphase 3since Apr 3, 2026Dec 12, 2023Jan 1, 2027phase 1 · NCT06179160

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 12, 2023First study: phase 1 study in Colorectal NeoplasmsFirst studyNCT06179160 · 710 planned · United States, Australia, Belgium and more
  2. Apr 3, 2026Phase 3 study in Pancreatic NeoplasmsPhase 3 reachedNCT07522073 · 588 planned · United States, Australia, Austria and more
  3. Sep 4, 20263 phase 1 studiesNCT07814404, NCT07853040, NCT07854249

Ahead

  1. Jan 1, 2027Primary completion: phase 1 study in Colorectal NeoplasmsNCT06179160
  2. Mar 30, 2027Primary completion: phase 1 study in Renal InsufficiencyNCT07854249
  3. Mar 31, 2027Primary completion: phase 1 study in Hepatic InsufficiencyNCT07853040
  4. Sep 15, 2028Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07522073

TargetBeta

KRAS →read by rule
“An orally bioavailable inhibitor of the oncogenic KRAS substitution mutation G12D, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07854249Renal Insufficiency1Not yet recruitingMar 30, 202724
NCT07853040Hepatic Insufficiency · United States1RecruitingMar 31, 202724
NCT07814404Healthy Participants · United States1CompletedOct 15, 202610
NCT07522073Pancreatic Neoplasms · United States, Australia, Austria and more3RecruitingSep 15, 2028588
NCT06179160Colorectal Neoplasms · United States, Australia, Belgium and more1RecruitingJan 1, 2027710

How it is read

Names in the registry

  • “INCB161734”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.